News

Shyft (NASDAQ:SHYF) Misses Q4 Sales Targets

Vehicle manufacturer Shyft (NASDAQ:SHYF) fell short of the market’s revenue expectations in Q4 CY2024, with sales flat year on year at $201.4 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $920 million at the midpoint. Its non-GAAP profit of $0.15 per share was 18.4% above analysts’ consensus estimates.

Walmart-backed PhonePe prepares for Indian stock market debut

Walmart-backed Indian fintech firm PhonePe is beginning preparatory steps for a public listing on the country's stock exchanges, the company said on Thursday. "PhonePe's strong top-line and bottom-line growth across its diverse business portfolio, as detailed in its FY23-24 annual report, makes this a suitable time to prepare for a public listing," the company said in a statement. The Indian stock market saw a significant upswing for much of 2024, with many companies launching their IPOs, but a downturn since October has weighed on investor sentiment.

Leonardo DRS (NASDAQ:DRS) Posts Better-Than-Expected Sales In Q4, Full-Year Sales Guidance is Optimistic

Aerospace and defense company Leonardo DRS (NASDAQ:DRS) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.9% year on year to $981 million. The company’s full-year revenue guidance of $3.48 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $0.38 per share was 7.6% above analysts’ consensus estimates.

Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $697.5 million at the midpoint. Its non-GAAP profit of $0.44 per share was 7.9% above analysts’ consensus estimates.

Baxter (NYSE:BAX) Beats Q4 Sales Targets, Stock Soars

Healthcare company Baxter International (NYSE:BAX) beat Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $2.75 billion. On the other hand, next quarter’s revenue guidance of $2.58 billion was less impressive, coming in 1.4% below analysts’ estimates. Its non-GAAP profit of $1.89 per share was significantly above analysts’ consensus estimates.